The popularity of Viagra initially drove a boom for pharma, but recent shifts present a uncertain scenario for investors. Generic versions are reducing earnings, and continued legal battles add more complexity to the https://shaniaurvy102780.post-blogs.com/62031958/the-blue-pill-and-big-pharma-a-precarious-investment